Abstract: Disclosed herein are compositions and methods for modulating cereblon neosubstrates. A small molecule modulator of Formula (I*), or a pharmaceutically acceptable salt or solvate thereof can be used to modulate cereblon neosubstrates.
Type:
Grant
Filed:
November 17, 2020
Date of Patent:
October 3, 2023
Assignees:
VIVIDION THERAPEUTICS, INC., THE SCRIPPS RESEARCH INSTITUTE
Inventors:
Benjamin F. Cravatt, Matthew Patricelli, Dean Stamos, Gabe Simon, Benjamin Horning, David Weinstein, Ekaterina Vinogradova
Abstract: Disclosed herein are compositions and methods for modulating cereblon neosubstrates. A small molecule modulator of Formula (I*), or a pharmaceutically acceptable salt or solvate thereof can be used to modulate cereblon neosubstrates.
Type:
Grant
Filed:
July 3, 2019
Date of Patent:
December 22, 2020
Assignees:
VIVIDION THERAPEUTICS, INC., THE SCRIPPS RESEARCH INSTITUTE
Inventors:
Benjamin F. Cravatt, Matthew Patricelli, Dean Stamos, Gabe Simon, Benjamin Horning, David Weinstein, Ekaterina Vinogradova
Abstract: Disclosed herein are in vivo engineered cereblon protein and methods of making the same. The in vivo engineered cereblon protein can include a site-specific non-naturally occurring modification at cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO:2 or 3, the modification comprising a moiety resulting from an in vivo Michael addition reaction between an exogenous Michael acceptor and the cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO:2 or 3.
Type:
Grant
Filed:
August 8, 2019
Date of Patent:
September 22, 2020
Assignees:
VIVIDION THERAPEUTICS, INC., THE SCRIPPS RESEARCH INSTITUTE
Inventors:
David Weinstein, Benjamin F. Cravatt, Matthew Patricelli, Dean Stamos, Gabe Simon, Benjamin Horning, Ekaterina Vinogradova, Brian Nordin, Kristen Baltgalvis, Todd Kinsella